Abstract:3505 Background: Immune checkpoint inhibitors have been used in neoadjuvant setting and showed promising clinical benefits in various tumors. Herein, we evaluate IBI310 plus sintilimab as neoadjuvant treatment in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) colorectal cancer (CRC) in a randomized, open-labeled, phase Ib study. Methods: Previously untreated pts with locally advanced (stage IIB-III), resectable, MSI-H/dMMR CRC were enrolled and randomized to receive 1 cycle of IBI310 1mg/kg plus 2 cycles of sintilimab 200 mg Q3W (arm A) or 2 cycles of sintilimab 200 mg Q3W (arm B) as neoadjuvant treatment. The stratification factors were risk evaluation at baseline (high risk: stage T4 or N2 vs low risk: stage T1-3 and N1) and age ( < 55 years vs ≥55 years). Curative resection was scheduled on day 36 to 56 after first dose of neoadjuvant treatment. Primary endpoint was pathological complete response (pCR) rate. Secondary endpoints included R0 resection rate and safety. Results: As of February 4, 2024, 101 pts were enrolled (males: 55.4%, median age: 56 years, ECOG PS 1: 54.5%, high risk: 76.2%) and randomized into arm A (n = 52) and arm B (n = 49). In arm A, 1 pt had early termination of treatment (withdrawal). In arm B, 4 pts had early termination of treatment (1 withdrawal, 1 died, 2 continued neoadjuvant sintilimab). Scheduled curative resection were performed in 51 (98.1%) pts in arm A and 45 (91.8%) pts in arm B. Postoperative evaluation revealed mismatch repair-proficient (pMMR) in 1 pt each in arm A and arm B. The pCR rates were 80.0% (40/50, 95%CI: 66.3-90.0) in arm A vs 47.7% (21/44, 95%CI: 32.5-63.3) in arm B (p = 0.0007). All pts received surgery had R0 resection. Median time between first dose of neoadjuvant treatment and surgery was 47 days (range: 35-82). Surgery delay occurred in 3 pts including 2 pts in arm A due to grade 2 hypothyroidism (2 days delay) and grade 1 hyperthyroidism (13 days delay), and 1 pt in arm B for other reason (26 days delay). Treatment-emergent adverse events (TEAEs) occurred in 46 pts (88.5%, grade≥3 in 13 pts) in arm A and 39 pts (79.6%, grade≥3 in 9 pts) in arm B. Immune-related adverse events (irAEs) occurred in 22 pts (42.3%) in arm A and 18 pts (36.7%) in arm B. Grade ≥3 irAEs occurred in 3 pts in arm A, including immune-mediated myocarditis, ileus and enteritis, and in 4 pts in arm B, including alanine aminotransferase increased, rash, hypothyroidism and myocarditis. Serious TRAEs occurred in 4 (7.7%) pts in arm A and 3 (6.1%) pts in arm B. TRAE leading to death occurred in 1 pt in arm B (myocarditis). Conclusions: Neoadjuvant IBI310 plus sintilimab significantly improved pCR rate than sintilimab alone in MSI-H/dMMR CRC. The safety profiles were comparable and manageable in both treatment arms. Clinical trial information: NCT05890742 .

Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Microsatellite Instability-High Gastrointestinal Malignancies: A Case Series

Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis

Preoperative (neoadjuvant) Therapy with Tislelizumab for Locally Advanced Colorectal Cancer with High Microsatellite Instability or Deficient Mismatch Repair: an Open-Label, Single-Arm, Multicenter Phase II Study.

The Safety and Efficacy of Immune Checkpoint Inhibitor in Combination with FOLFOX As Neoadjuvant/adjuvant Therapy in Patients with Locally Advanced Colon Cancer.

Neoadjuvant immunotherapy with ipilimumab plus nivolumab in mismatch repair deficients/microsatellite instability-high colorectal cancer: a preliminary report of case series

Efficacy and Safety of Preoperative Immunotherapy in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Gastrointestinal Malignancies

Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities

Efficacy and toxicity of neoadjuvant immune checkpoint inhibitors in resectable gastric cancer: A meta-analysis and systematic review.

Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis

Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?

Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers

The Relationship Between Mismatch Repair (MMR) Proteins Status and the Response to Conventional Neoadjuvant Therapy in Colorectal Cancer (CRC).

Neoadjuvant Treatment of IBI310 (Anti-Ctla-4 Antibody) Plus Sintilimab (Anti-Pd-1 Antibody) in Patients with Microsatellite Instability-High/mismatch Repair-Deficient Colorectal Cancer: Results from a Randomized, Open-Labeled, Phase Ib Study.

Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H / dMMR rectal cancer: A prospective, multicenter, phase Ib study

Prevalent Pseudoprogression and Pseudoresidue in Patients with Rectal Cancer Treated with Neoadjuvant Immune Checkpoint Inhibitors

The efficacy and safety of neoadjuvant immunotherapy in patients with deficient mismatch repair/microsatellite instability–high (dMMR/MSI-H) localized and oligometastatic colon cancer: Data from the real world.

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

Efficacy and Safety of Immune Checkpoint Inhibitors in Proficient Mismatch Repair (pmmr)/ Non-Microsatellite Instability-High (Non-Msi-h) Metastatic Colorectal Cancer: a Study Based on 39 Cohorts Incorporating 1723 Patients.

Immunoneoadjuvant Therapy with Immune Checkpoint Inhibitors of Gastric Cancer: an Emerging Exemplification

Neoadjuvant immunotherapy in microsatellite instability-high (MSI-H) duodenal adenocarcinoma leads to pathological complete response and paves the way for new strategies